AGL agilon health, inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AGL Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Care Facilities
Current Price
Live
$0.99
Analyst Target
$0.99
-0.5%
Downside
52W High
$6.08
52W Low
$0.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$410.85M
P/E
N/A
ROE
-73.3%
Profit margin
-5.2%
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
92%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Profitability metrics are deeply negative, including a -5.24% profit margin, -8.86% operating margin, and a disastrous -73.31% ROE, signaling severe capital inefficiency. Despite a low Price/Sales ratio of 0.07 and a current price of $0.99, the company is unprofitable with declining revenue and negative earnings momentum, while the market has priced in extreme pessimism, as seen in a 5Y return of -96.8%. Analysts unanimously recommend a 'hold' with a target price equal to the current price, suggesting no near-term upside expectation.
Key Strengths
Low Price/Sales ratio of 0.07 suggests potential undervaluation relative to revenue
Debt/Equity ratio of 0.12 indicates minimal leverage and low financial risk from debt
Current Ratio of 1.08 and Quick Ratio of 1.04 show just sufficient short-term liquidity
Recent 1-month price surge of +41.4% may indicate speculative interest or short-term catalyst
Peer comparison shows lower debt than sector average (0.12 vs 2.42)
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor earnings stability
Gross Margin of -1.83% means core operations are unprofitable before overhead
ROE of -73.31% and ROA of -12.52% reflect severe inefficiency in equity and asset utilization
Revenue growth is negative YoY (-1.10%), indicating shrinking top line
Forward P/E of -2.55 and negative earnings trend signal persistent unprofitability
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
45
20
15
30
0
AI Verdict
Highly risky with poor fundamentals and no clear catalyst for recovery
Key drivers: Negative profitability across all margins, Low Piotroski score and missing Altman Z-Score, Shrinking revenue and negative earnings growth, Extremely poor long-term price performance
Confidence
94%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Sales ratio (0.07) suggests potential value
- Price/Book of 1.34 is below many growth-oriented healthcare peers
Watchpoints
- P/E and Forward P/E are negative, invalidating traditional valuation
- No Graham Number or Intrinsic Value available due to unprofitability
Future
20/100
Ref Growth rates
Positives
- Slight YoY EPS growth of +3.6% despite deep losses
Watchpoints
- Revenue growth is negative (-1.10% YoY)
- Forward P/E of -2.55 implies no near-term profitability
- Q/Q EPS growth of -8.0% shows deteriorating earnings
Past
15/100
Ref Historical trends
Positives
- One quarter beat in the last four (25% beat rate)
- Some quarters showed positive earnings surprises (e.g., +436.7%)
Watchpoints
- 14 out of 20 quarters missed estimates
- Frequent large negative surprises (e.g., -225.7%, -137.0%)
- 5Y price return of -96.8% reflects sustained value destruction
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 4/9 is above distress threshold
- Low Debt/Equity ratio of 0.12 reduces bankruptcy risk
Watchpoints
- Piotroski score indicates weak financial health
- Altman Z-Score is unavailable, creating uncertainty
- ROE of -73.31% and negative margins signal operational distress
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (Dividend Yield: N/A)
- Dividend Strength score is 0/100
- Payout Ratio is 0.00% due to lack of dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.99
Analyst Target
$0.99
Upside/Downside
-0.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AGL and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AGL
agilon health, inc.
Primary
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
ABSI
Absci Corporation
Peer
|
-87.7% | +9.1% | -48.9% | +0.8% | -12.2% | +3.9% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-42.6% | +262.8% | +3.5% | -21.9% | -45.7% | -2.1% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.9% | -19.8% | -4.9% | +24.1% | -3.3% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.55
PEG Ratio
N/A
P/B Ratio
1.34
P/S Ratio
0.07
EV/Revenue
0.02
EV/EBITDA
-0.4
Market Cap
$410.85M
Profitability
Profit margins and return metrics
Profit Margin
-5.24%
Operating Margin
-8.86%
Gross Margin
-1.83%
ROE
-73.31%
ROA
-12.52%
Growth
Revenue and earnings growth rates
Revenue Growth
-1.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
1.08
Good
Quick Ratio
1.04
Good
Cash/Share
$0.75
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-04
$-0.27
-64.1% surprise
2025-08-04
$-0.25
-137.0% surprise
2025-05-06
$0.03
+436.7% surprise
Healthcare Sector Comparison
Comparing AGL against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-73.31%
This Stock
vs
-56.86%
Sector Avg
+28.9%
(Excellent)
Profit Margin
-5.24%
This Stock
vs
-20.8%
Sector Avg
-74.8%
(Weaker)
Debt to Equity
0.12
This Stock
vs
2.68
Sector Avg
-95.5%
(Less Debt)
Revenue Growth
-1.1%
This Stock
vs
62.23%
Sector Avg
-101.8%
(Slower)
Current Ratio
1.08
This Stock
vs
3.45
Sector Avg
-68.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | |
|
ABSI
Absci Corporation
|
BEARISH | $398.48M | - | -55.7% | -% | $2.65 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $395.29M | - | -% | -158.9% | $3.24 | |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $435.26M | - | -15.3% | -9.0% | $10.56 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-09 | SCHWANEKE JEFFREY A | Chief Financial Officer | Stock Award | 600,000 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
12 analysts
Barclays
2025-11-06
Underweight
Underweight
Wells Fargo
2025-11-05
Overweight
Overweight
Wells Fargo
2025-10-07
Overweight
Overweight
Bernstein
2025-08-20
Outperform
Market Perform
Jefferies
2025-08-15
Hold
Hold
Baird
2025-08-14
Neutral
Neutral
Benchmark
2025-08-06
Buy
Buy
Barclays
2025-08-06
Underweight
Underweight
Citigroup
2025-08-06
Buy
Neutral
Past News Coverage
Recent headlines mentioning AGL from our newsroom.
Newest → oldest
No matching news yet.